221 



- 1 9 5 - 



633. DORCHE, J., and CASTAING, M. 



Sur la recherche des substances pyrogenes dans les solutes In- 

 jectables; les essais bases sur la leucocytose du lapln (Re- 

 search on pyrogenic substances in injectable solutes; tests 

 based on leukocytosis of the rabbit) 



Ann, pharm, franc, 8:353-357, 1950 



The leukocyte count is too variable in the rabbit for use as a 

 test factor for pyrogens in solutions intended for parenteral 

 injection. Injection of pyrogen-free solutions and observa- 

 tions of the increases in the poljmorphonuclear cell count should 

 precede the administration of pyrogenic solutions. Differences 

 between the grades of polynucleosis should be recorded for use 

 as a test control measure, 



634. DORCHE, J, and CASTAING, M. 



Sur la recherche des substances pyrogenes dans les solutes in- 

 Jectables; attenuation des proprietes pyrogenes au cours de la 

 conservation des solutes (Research on pyrogenic substances in 

 injectable solutes. Reduction of pyrogenic properties during 

 the storage of solutions) 



Ann. pharm. franc, 8:365-368, 1950 



Prolonged storage of solutions reduces the pyrogenic factors 

 in most solutions. Glucose solutions are exceptions, 



635. DORCHE, J., BOUTHIER, G,, ARDIET, M. T., and CASTAING, M. 



Sur la recherche des substances pyrogenes dans les solutes in- 

 Jectablesj Commentaires et application de I'essai de la Pharma- 

 cop^e francaise (Research on pyrogenic substances in injectable 

 solutes. Commentary on and application of the bio-assay according 

 to the French Pharmacopoeia) 



Ann. pharm. franc, 8:358-365, 1950 



Factors which influence the bio-assay may be physiologic or 

 cheraic in nature. Hypotonic solutions may yield false positive 

 readings for pyrogenic content. The sensitiveness of the rabbit 

 to handling is noted; special precautions must be taken in plac- 

 ing the rectal thermometer during the test, 



636. FARR, R. S. and LEQUIRE, V. S. 



Leukocytic and pyrogenic effects of typhoid vaccine and augmen- 

 tation by homologous plasma 



